Closed · W81XWH-15-GWIRP-ITEA · CFDA 12.420 · Discretionary
DoD Gulf War Illness Innovative Treatment Evaluation Award
Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- October 29, 2015
- Close date
- 3
- Expected awards
The verdict
DoD Gulf War Illness Innovative Treatment Evaluation Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 3 expected awards. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.
- Varies
- award range
- Closed
- application status
- 3
- expected awards
- 12.420
- CFDA program
Archived opportunity record
DoD Gulf War Illness Innovative Treatment Eva… is closed (last close October 29, 2015). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.
According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.
Deadline tracker
Application window closed
Closed October 29, 2015
Est. Total Funding
$3,400,000
Expected Awards
3
Instrument
Grant
Description
The FY15 GWIRP is offering two award mechanisms to evaluate potential interventions for GWI: the Innovative Treatment Evaluation Award and the Clinical Trial Award. The Innovative Treatment Evaluation Award, described in this Program Announcement, supports the initial evaluation of a treatment or intervention in early phase or pilot clinical trials (Phase 0, I, or I/II), and does not require preliminary data. These trials will hereafter collectively be referred to as “pilot clinical trials.” In contrast, the Clinical Trial Award is intended to support larger, more definitive (Phase II-III, U.S. Food and Drug Administration [FDA] device class I-III) clinical trials. (For information about the Clinical Trial Award, see http://cdmrp.army.mil/funding/gwirp.shtml.) The Innovative Treatment Evaluation Award mechanism was first offered in FY08. Since then, 42 Innovative Treatment Evaluation Award applications have been received, and 15 have been recommended for funding. The Innovative Treatment Evaluation Award mechanism supports the early systematic evaluation of innovative interventions with the potential to impact the health and lives of Veterans with GWI. The results of preliminary studies funded by this award should have the potential to provide clinical proof-of-principle data and support future development of broader efficacy studies of the proposed interventions. Innovation is an important component of the Innovative Treatment Evaluation Award. An application may demonstrate innovation not only by investigating a novel therapeutic approach for GWI, but also by studying a treatment that may have been utilized for other chronic multisymptom illnesses, but has not yet been studied in Veterans with GWI. For example, a pharmacological treatment or nutritional supplement suggested by previous research to be beneficial for fibromyalgia or chronic fatigue syndrome could be evaluated in Veterans with GWI under the Innovative Treatment Evaluation Award. However, the focus of the research must be clearly on GWI (and Veterans of the 1990-1991 Gulf War) and not on another disease process or Veteran cohort. Given the emphasis on innovation in the Innovative Treatment Evaluation Award, applications are not required to include preliminary data. If preliminary data are provided, the data do not necessarily have to come from the GWI research field. Whether or not preliminary data are included in the application, the proposed research project should be based on sound scientific rationale that is established through logical reasoning and critical review and analysis of the literature. Trials of treatments or interventions for which considerable preliminary and/or preclinical data have been developed should be proposed under the Clinical Trial Award (see http://cdmrp.army.mil/gwirp/default.shtml). This award mechanism is designed to evaluate a broad scope of treatment approaches with potential for application to GWI. Treatment approaches may include pharmacologic or other physiological interventions, including conventional, alternative, or complementary (combination of alternative and conventional) approaches. A variety of experimental and non-experimental study designs are acceptable under this award mechanism. The proposed study design will depend on the specific treatment or intervention to be assessed, resources available to clinical investigators, and the level of evidence currently available to support the proposed treatment for GWI. Examples of potential prospective designs may include systematic case series, prospective outcome evaluation studies, small-scale randomized trials, a combination of these, or other innovative prospective methods. Also of interest are interventions based on biological alterations identified in Veterans with GWI. All studies involving interventions, regardless of design, are considered clinical trials. The Innovative Treatment Evaluation Award supports execution of clinical trials with the potential to have a significant impact on the health and lives of Veterans with GWI. Health outcomes of interest should include improvements in overall functional status or in symptom complexes (e.g., cognitive function, musculoskeletal/pain symptoms, gastrointestinal symptoms, fatigue, respiratory problems, skin abnormalities, sleep difficulties and others) individually and/or as they may interact with each other.
Catch-all / unrestricted eligibility mark · W81XWH-15-GWIRP-ITEA
Grants.gov marks DoD Gulf War Illness Innovative Treatment Eva… with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).
- Code 99
- Unrestricted / see official listing
Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk 301-682-5507
More from Defense Health Agency Contracting Activity - DHACA
DoW Neurofibromatosis Synergistic Idea Award
DoW Neurofibromatosis Investigator-Initiated Research Award
DoW Neurofibromatosis Research Academy – Scholar Award
DoW Neurofibromatosis Exploration-Hypothesis Development Award
DOW Combat Readiness – Medical Research Program Translational Research Award
What to do next
DoD Gulf War Illness Innovative Treatment Eva… is closed; use the parent program and agency catalog for the next funding cycle.
- Browse open federal opportunities in the same category when this listing is closed. Open opportunities
- Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
- Compare award ranges across federal categories before you pick a single CFDA. All categories
Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |